UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

Multiple sclerosis, 2012-02, Vol.18 (2), p.143-152

2012

Volltextzugriff (PDF)

The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis

Journal of the neurological sciences, 2018-07, Vol.390, p.89-93

2018

Volltextzugriff (PDF)

Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls

Multiple sclerosis and related disorders, 2021-10, Vol.55, p.103170-103170, Article 103170

2021

Volltextzugriff (PDF)

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

Journal of inflammation research, 2018-01, Vol.11, p.215-226

2018

Volltextzugriff (PDF)

CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study

Brain pathology (Zurich, Switzerland), 2021-11, Vol.31 (6), p.e12969-n/a

2021

Volltextzugriff (PDF)

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF

Multiple sclerosis, 2015-07, Vol.21 (8), p.1036-1044

2015

Volltextzugriff (PDF)

Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab

Frontiers in neurology, 2022-03, Vol.13, p.819911-819911

2022

Volltextzugriff (PDF)

IgM to phosphatidylcholine in multiple sclerosis patients: from the diagnosis to the treatment

Therapeutic Advances in Neurological Disorders, 2023-01, Vol.16, p.17562864231189919-17562864231189919

2023

Volltextzugriff (PDF)

Prise en charge des leuco-encéphalopathies multifocales progressives (LEMP) et des syndromes de reconstitution immunitaire (IRIS) sous natalizumab : rôle de l’IRM cérébrale

Revue neurologique, 2012-04, Vol.168, p.A127-A128

2012

Volltextzugriff (PDF)

Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies

Journal of medical economics, 2023-12, Vol.26 (1), p.494-502

2023

Volltextzugriff (PDF)

Course of neuropsychological impairment during natalizumab‐associated progressive multifocal leukoencephalopathy

European journal of neurology, 2021-03, Vol.28 (3), p.921-927

2021

Volltextzugriff (PDF)

4-Week toxicity study of biosimilar natalizumab in comparison to Tysabri® by repeated intravenous infusion to cynomolgus monkeys

Drug and chemical toxicology (New York, N.Y. 1978), 2022-03, Vol.45 (2), p.499-506

2022

Volltextzugriff (PDF)

Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress

European journal of pharmacology, 2014-05, Vol.730, p.26-30

2014

Volltextzugriff (PDF)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis

Frontiers in neurology, 2021-04, Vol.12, p.650530-650530

2021

Volltextzugriff (PDF)

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy

Multiple sclerosis, 2012-01, Vol.18 (1), p.108-112

2012

Volltextzugriff (PDF)

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies

Journal of neuroinflammation, 2016-06, Vol.13 (1), p.164, Article 164

2016

Volltextzugriff (PDF)

Monoclonal Antibodies in Multiple Sclerosis: Present and Future

Biomedicines, 2019-03, Vol.7 (1), p.20

2019

Volltextzugriff (PDF)

Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy

Multiple sclerosis, 2017-05, Vol.23 (6), p.830-835

2017

Volltextzugriff (PDF)

Multiple Sclerosis: Diagnosis and Treatment

Rivera, Víctor M

2022

Volltextzugriff (PDF)

Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients

Multiple sclerosis and related disorders, 2014-07, Vol.3 (4), p.520-526

2014

Volltextzugriff (PDF)

Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?

Annals of neurology, 2006-08, Vol.60 (2), p.162-173

Koralnik, Igor J.

2006

Volltextzugriff (PDF)

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis

Multiple sclerosis, 2011, Vol.17 (6), p.708-719

2011

Volltextzugriff (PDF)

Anti-α4β1 Integrin Antibodies Attenuated Brain Inflammatory Changes in a Mouse Model of Alzheimer's Disease

Current Alzheimer research, 2018, Vol.15 (12), p.1123-1135

2018

Volltextzugriff (PDF)

Re-evaluating the Incidence of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Multiple sclerosis and related disorders, 2016-07, Vol.8, p.145-150

2016

Volltextzugriff (PDF)

Smokers run increased risk of developing anti-natalizumab antibodies

Multiple sclerosis, 2014-07, Vol.20 (8), p.1081-1085

2014

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(48)

Publikationsform

Sprache

Englisch
(56)
Französisch
(2)

Erscheinungsjahr

n.n

Thema

Tysabri
(48)
Life Sciences & Biomedicine
(46)
Science & Technology
(46)
Natalizumab
(39)
Humans
(36)
Neurosciences & Neurology
(36)
Multiple Sclerosis
(34)
Clinical Neurology
(33)
Neurology
(28)
Neurosciences
(28)
Female
(19)
Adult
(18)
Biological And Medical Sciences
(18)
Medical Sciences
(18)
Male
(16)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(15)
Progressive Multifocal Leukoencephalopathy
(15)
Multiple Sclerosis - Drug Therapy
(13)
Middle Aged
(12)
Antibodies, Monoclonal, Humanized
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis

Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF

Alterations of the miR-126-3p/POU2AF1/Spi-B Axis and JCPyV Reactivation in Multiple Sclerosis Patients Receiving Natalizumab

IgM to phosphatidylcholine in multiple sclerosis patients: from the diagnosis to the treatment

Prise en charge des leuco-encéphalopathies multifocales progressives (LEMP) et des syndromes de reconstitution immunitaire (IRIS) sous natalizumab : rôle de l’IRM cérébrale

Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies

Course of neuropsychological impairment during natalizumab‐associated progressive multifocal leukoencephalopathy

4-Week toxicity study of biosimilar natalizumab in comparison to Tysabri® by repeated intravenous infusion to cynomolgus monkeys

Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: Relationship to oxidative stress

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis

Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy

New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies

Monoclonal Antibodies in Multiple Sclerosis: Present and Future

Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy

Multiple Sclerosis: Diagnosis and Treatment

Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients

Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis

Anti-α4β1 Integrin Antibodies Attenuated Brain Inflammatory Changes in a Mouse Model of Alzheimer's Disease

Re-evaluating the Incidence of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Smokers run increased risk of developing anti-natalizumab antibodies

Suchergebnisse filtern